Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.
Roberto Ceravolo, Fabiana Lucà, Michele M Gulizia et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effects of semaglutide in adults with obesity-related heart failure with preserved ejection fraction (HFpEF). Analyzing data from six randomized trials involving 4,216 participants, the study found that semaglutide significantly reduced NT-proBNP levels by 119.7 pg/ml and improved Kansas City Cardiomyopathy Questionnaire scores by 8.27 points, while also lowering the risk of heart-failure hospitalization (odds ratio 0.81).
Key findings
- Semaglutide reduced NT-proBNP levels by 119.7 pg/ml (95% CI -144.4 to -95.1; p <0.001).
- KCCQ scores improved by 8.27 points (95% CI 6.04 to 10.50; p <0.001) with semaglutide.
- The odds of heart-failure hospitalization were reduced (odds ratio 0.81; 95% CI 0.75 to 0.88; p <0.001).
Why it matters
The findings highlight the potential of semaglutide as a therapeutic option for patients with obesity-related HFpEF, addressing a condition with limited treatment alternatives. Improved biomarkers and symptom scores may enhance patient quality of life and reduce hospitalization rates.